Supplementary Figures 1 - 8 from Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4<sup>+</sup> T-Cell Responses through the PD-1–PD-L1 Axis

PDF file - 133KB, Immunofluorescence staining (IF) of CD11b+ myeloid cells on spleen and tumor samples (S1). CTX+CD4 AT therapy induces an inflammatory immune milieu (S2). Chemoimmunotherapy leads to myeloid cell expansion in mice with lung metastasis of CT26HA colon cancer (S3). Therapy-induced monocytes can suppress CD4+ T cell activation in response to either antigen-specific or nonspecific stimulation (S4). Dose effect of CTX on myeloid cell induction (S5). Monocytic myeloid suppressor cells can be induced by doxorubicin and melphalan (S6). Low dose gemcitabine following CTX+CD4 AT therapy confers long-term survival benefit to mice with lung metastasis of CT26HA colon cancer (S7). Low dose 5-fluorouracil (5-FU) reduces therapy-induced monocytes (S8).